menu

Loading...

PULM Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

2.325

Open

2.140

VWAP

2.02

Vol

398.77K

Mkt Cap

6.90M

Low

1.850

Amount

806.19K

EV/EBITDA(TTM)

--

Total Shares

3.65M

EV

6.83M

EV/OCF(TTM)

--

P/S(TTM)

--

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

Show More

Events Timeline

(ET)

2026-03-02

08:30:00

Gyre Therapeutics Acquires Cullgen for $300M

2026-03-02

08:10:00

Pulmatrix Terminated Merger Agreement by Cullgen

2025-12-18 (ET)

2025-12-18

08:20:00

Pulmatrix and Cullgen Waive 'No Solicitation' Clause in Merger Agreement

2025-10-16 (ET)

2025-10-16

08:16:04

Pulmatrix announces Q3 earnings per share of 24 cents, compared to a loss of 71 cents in the previous year.

2025-10-16

08:07:36

Pulmatrix Considering Sale of Patent Portfolio for iSPERSE Technology

2025-08-06 (ET)

2025-08-06

08:12:23

Pulmatrix to potentially divest its patent portfolio for iSPERSE technology

News

stocktwits

03-02stocktwits

Gyre Therapeutics Acquires Cullgen in $300 Million All-Stock Deal

PRnewswire

03-02PRnewswire

Cullgen Terminates Merger Agreement with Pulmatrix

seekingalpha

02-26seekingalpha

Pulmatrix Reports Q4 Results with Significant Losses

PRnewswire

02-26PRnewswire

Pulmatrix Reports 2025 Financial Results and Merger Progress

PRnewswire

2025-12-18PRnewswire

Pulmatrix and Cullgen Update on Merger Approval Process

Newsfilter

2025-12-18Newsfilter

Pulmatrix and Cullgen Update on Merger Approval Process

Valuation Metrics

The current forward P/E ratio for Pulmatrix Inc (PULM.O) is -0.46, compared to its 5-year average forward P/E of -1.08. For a more detailed relative valuation and DCF analysis to assess Pulmatrix Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.08

Current PE

-0.46

Overvalued PE

-0.35

Undervalued PE

-1.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

4.65

Current PS

1.18

Overvalued PS

10.81

Undervalued PS

-1.52

Financials

AI Analysis

Annual

Quarterly

Whales Holding PULM

Trading Trends

People Also Watch

Frequently Asked Questions

What is Pulmatrix Inc (PULM) stock price today?

The current price of PULM is 1.89 USD — it has decreased -36.79

What is Pulmatrix Inc (PULM)'s business?

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

What is the price predicton of PULM Stock?

Wall Street analysts forecast PULM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PULM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Pulmatrix Inc (PULM)'s revenue for the last quarter?

Pulmatrix Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Pulmatrix Inc (PULM)'s earnings per share (EPS) for the last quarter?

Pulmatrix Inc. EPS for the last quarter amounts to -0.25 USD, decreased -53.70

How many employees does Pulmatrix Inc (PULM). have?

Pulmatrix Inc (PULM) has 2 emplpoyees as of March 03 2026.

What is Pulmatrix Inc (PULM) market cap?

Today PULM has the market capitalization of 6.90M USD.